印度重症医学会指南:重症患者碳青霉烯耐药肠杆菌目、碳青霉烯耐药鲍曼不动杆菌和碳青霉烯耐药铜绿假单胞菌治疗的循证推荐:GRADE方法
该指南针对印度ICU中碳青霉烯耐药革兰阴性菌(CRE、CRAB、CRPA)感染死亡率高、缺乏标准化治疗指南的问题,按GRADE框架系统检索PubMed至2024年10月,纳入52项研究(36项评估多黏菌素/黏菌素,16项评估舒巴坦),进行Meta分析并经结构化专家共识形成推荐。结果显示:CRE中β-内酰胺/β-内酰胺酶抑制剂联合方案治愈率58.7% vs 多黏菌素方案48.9%,不良事件10.3% vs 13.3%,支持强推荐非多黏菌素治疗(证据确定性极低);CRAB中含舒巴坦方案(尤其舒巴坦-度洛巴坦)治愈率61.9% vs 39.7%,肾毒性13% vs 38%,支持强推荐(极低确定性);CRPA中疗效相当但多黏菌素毒性更高(42.1% vs 17.9%),弱推荐非多黏菌素方案(极低确定性)。结论认为减少多黏菌素使用可能改善结局并降低毒性,但迫切需要稳健的随机试验。
要点
- CRE感染:BL/BLI联合方案较多黏菌素方案治愈率更高(58.7% vs 48.9%)、不良事件更少(10.3% vs 13.3%),指南强推荐非多黏菌素治疗(证据确定性极低)。
- CRAB感染:含舒巴坦方案(尤其舒巴坦-度洛巴坦)治愈率61.9% vs 39.7%、肾毒性13% vs 38%,指南强推荐含舒巴坦方案(证据确定性极低)。
- CRPA感染:非多黏菌素方案与多黏菌素疗效相当,但多黏菌素毒性更高(42.1% vs 17.9%),指南弱推荐非多黏菌素方案(证据确定性极低)。
- 该指南基于52项研究(36项多黏菌素/黏菌素、16项舒巴坦)的Meta分析及GRADE专家共识,针对印度ICU重症患者。
- 指南结论指出减少多黏菌素使用可能改善结局并降低毒性,但迫切需要稳健的随机试验。
适用人群与场景
- 印度ICU中碳青霉烯耐药革兰阴性菌(CRE、CRAB、CRPA)感染的重症患者。
处置流程与药物剂量
- CRE感染:强推荐非多黏菌素方案(如BL/BLI联合方案),证据确定性极低。
- CRAB感染:强推荐含舒巴坦方案(尤其舒巴坦-度洛巴坦),证据确定性极低。
- CRPA感染:弱推荐非多黏菌素方案,证据确定性极低。
研究设计与关键结果
- 系统评价纳入52项研究:36项评估多黏菌素/黏菌素方案,16项评估舒巴坦方案。
- CRE:BL/BLI联合方案 vs 多黏菌素方案,治愈率58.7% vs 48.9%,不良事件10.3% vs 13.3%,死亡率有多黏菌素方案降低趋势。
- CRAB:含舒巴坦方案(尤其舒巴坦-度洛巴坦)vs 对照,治愈率61.9% vs 39.7%,肾毒性13% vs 38%。
- CRPA:非多黏菌素方案与多黏菌素方案疗效相当,多黏菌素毒性更高(42.1% vs 17.9%)。
证据类型、等级与局限
- 证据类型:GRADE框架系统评价与Meta分析(PubMed检索至2024年10月)及结构化专家共识形成的指南。
- 推荐强度:CRE非多黏菌素强推荐、CRAB含舒巴坦强推荐、CRPA非多黏菌素弱推荐;证据确定性均为极低。
- 局限:纳入研究的证据确定性均为极低;结论指出迫切需要稳健的随机试验。
对床旁实践的改变
- 对印度ICU中CRE感染的重症患者,指南强推荐使用非多黏菌素方案而非多黏菌素方案。
- 对印度ICU中CRAB感染的重症患者,指南强推荐含舒巴坦方案(尤其舒巴坦-度洛巴坦)。
- 对印度ICU中CRPA感染的重症患者,指南弱推荐非多黏菌素方案。
- 指南结论认为,减少多黏菌素使用可能改善结局并降低毒性,但迫切需要稳健的随机试验。
指南或共识出处
- 印度重症医学会(Indian Society of Critical Care Medicine)指南,发表于Indian J Crit Care Med。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Carbapenem-resistant Enterobacterales (CRE), Acinetobacter baumannii (CRAB), and Pseudomonas aeruginosa (CRPA) are major antimicrobial resistance (AMR) threats in Indian intensive care units, with mortality rates often exceeding 40-70%. Despite the clinical burden, there is a lack of standardized treatment guidelines. This study aimed to develop Grading of Recommendations Assessment, Development and Evaluation (GRADE)-based recommendations for managing carbapenem-resistant gram-negative (CRGN) infections in critically ill patients.
METHODOLOGY: A systematic review was conducted following the GRADE framework. PubMed was searched through October 2024 for studies comparing polymyxin B/colistin with alternative regimens for CRE, CRAB, and CRPA, and sulbactam-based therapy vs comparators for CRAB. Meta-analyses were performed using RevMan. Evidence of certainty was graded, and recommendations were formulated through structured expert consensus. Outcomes included clinical cure, microbiological eradication, mortality, and adverse events (AEs).
RESULTS: Fifty-two studies were included: 36 evaluating polymyxin/colistin and 16 evaluating sulbactam. For CRE, β-lactam/β-lactamase inhibitor (BL/BLI) combinations achieved higher cure rates (58.7 vs 48.9%), fewer AEs (10.3 vs 13.3%), and trends toward reduced mortality compared with polymyxin-based regimens, leading to a strong recommendation for non-polymyxin therapy (very low certainty). For CRAB, sulbactam-based regimens, particularly sulbactam-durlobactam, showed superior cure rates (61.9 vs 39.7%) and reduced nephrotoxicity (13 vs 38%), supporting a strong recommendation (very low certainty). For CRPA, efficacy appeared comparable, but polymyxin therapy caused higher toxicity (42.1 vs 17.9%), resulting in a weak recommendation for non-polymyxin options (very low certainty).
CONCLUSION: These findings provide GRADE-based treatment recommendations for carbapenem-resistant infections in Indian ICUs. Non-polymyxin regimens are preferred for CRE and CRPA, while sulbactam-based therapy is favored for CRAB. This shift away from polymyxin use may improve outcomes and reduce toxicity, though robust randomized trials are urgently needed.
参考来源
- Todi SK, Jagiasi BG, Juneja D, et al. Indian Society of Critical Care Medicine Guidelines on Evidence-based Recommendations for the Treatment of Carbapenem-resistant Enterobacterales, Carbapenem-resistant Acinetobacter baumannii, and Carbapenem-resistant Pseudomonas aeruginosa in Critically Ill Patients: A GRADE-guided Approach. Indian J Crit Care Med. 2026. PMID: 42523687. doi:10.5005/jp-journals-10071-25216
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。